Linked Life Data

18418220

Source:http://linkedlifedata.com/resource/pubmed/id/18418220

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18418220rdf:typepubmed:Citationlld:pubmed
pubmed-article:18418220lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:18418220lifeskim:mentionsumls-concept:C0006826lld:lifeskim
pubmed-article:18418220lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:18418220lifeskim:mentionsumls-concept:C0679729lld:lifeskim
pubmed-article:18418220lifeskim:mentionsumls-concept:C1518578lld:lifeskim
pubmed-article:18418220lifeskim:mentionsumls-concept:C1522484lld:lifeskim
pubmed-article:18418220lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:18418220lifeskim:mentionsumls-concept:C0679246lld:lifeskim
pubmed-article:18418220lifeskim:mentionsumls-concept:C0246415lld:lifeskim
pubmed-article:18418220lifeskim:mentionsumls-concept:C0069717lld:lifeskim
pubmed-article:18418220lifeskim:mentionsumls-concept:C0036525lld:lifeskim
pubmed-article:18418220lifeskim:mentionsumls-concept:C1517927lld:lifeskim
pubmed-article:18418220lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:18418220lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:18418220lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:18418220lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:18418220lifeskim:mentionsumls-concept:C0239308lld:lifeskim
pubmed-article:18418220pubmed:issue5lld:pubmed
pubmed-article:18418220pubmed:dateCreated2008-4-17lld:pubmed
pubmed-article:18418220pubmed:abstractTextA phase II trial was performed to determine the efficacy and tolerance of docetaxel plus oxaliplatin with hematopoietic growth factor support in previously untreated patients with advanced gastroesophageal adenocarcinoma. Thirty-five patients were entered in this trial. Treatment consisted of 3-weekly docetaxel 80 mg/m2 and oxaliplatin 100 mg/m2 both infused on day 1. A prophylactic 5-day course of human granulocyte colony-stimulating factor 5 microg/kg/day was given subcutaneously, and erythropoietin (10,000 IU subcutaneously three times per week) was administered if hemoglobin was less than 12.0 mg/dl. The confirmed overall response rate was 34%, including two complete responses (6%) and 10 partial responses (28%). Fifteen patients (43%) had stable disease. The median time to response was 2.5 months (1-3.5), the median time to progression was 8.9 (4-42.5) months and the median overall survival time was 11.6 (2.5-51) months. Hematologic toxicity was common, though World Health Organization grade 3 or 4 neutropenia occurred only in six (17%) patients and anemia in six (17%) patients, respectively. Nonhematologic adverse reactions were usually mild-to-moderate. Our data suggest that the combination of docetaxel and oxaliplatin with granulocyte colony-stimulating factor and erythropoietin has a promising therapeutic index in patients with advanced gastroesophageal adenocarcinoma.lld:pubmed
pubmed-article:18418220pubmed:languageenglld:pubmed
pubmed-article:18418220pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18418220pubmed:citationSubsetIMlld:pubmed
pubmed-article:18418220pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18418220pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18418220pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18418220pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18418220pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18418220pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18418220pubmed:statusMEDLINElld:pubmed
pubmed-article:18418220pubmed:monthJunlld:pubmed
pubmed-article:18418220pubmed:issn0959-4973lld:pubmed
pubmed-article:18418220pubmed:authorpubmed-author:RadererMarkus...lld:pubmed
pubmed-article:18418220pubmed:authorpubmed-author:SchmidingerMa...lld:pubmed
pubmed-article:18418220pubmed:authorpubmed-author:Ba-SsalamahAh...lld:pubmed
pubmed-article:18418220pubmed:authorpubmed-author:BrodowiczThom...lld:pubmed
pubmed-article:18418220pubmed:authorpubmed-author:ZacherlJohann...lld:pubmed
pubmed-article:18418220pubmed:authorpubmed-author:ZielinskiChri...lld:pubmed
pubmed-article:18418220pubmed:authorpubmed-author:PluschnigUrsu...lld:pubmed
pubmed-article:18418220pubmed:authorpubmed-author:PüspökAndreas...lld:pubmed
pubmed-article:18418220pubmed:authorpubmed-author:HejnaMichaelMlld:pubmed
pubmed-article:18418220pubmed:issnTypePrintlld:pubmed
pubmed-article:18418220pubmed:volume19lld:pubmed
pubmed-article:18418220pubmed:ownerNLMlld:pubmed
pubmed-article:18418220pubmed:authorsCompleteYlld:pubmed
pubmed-article:18418220pubmed:pagination535-9lld:pubmed
pubmed-article:18418220pubmed:meshHeadingpubmed-meshheading:18418220...lld:pubmed
pubmed-article:18418220pubmed:meshHeadingpubmed-meshheading:18418220...lld:pubmed
pubmed-article:18418220pubmed:meshHeadingpubmed-meshheading:18418220...lld:pubmed
pubmed-article:18418220pubmed:meshHeadingpubmed-meshheading:18418220...lld:pubmed
pubmed-article:18418220pubmed:meshHeadingpubmed-meshheading:18418220...lld:pubmed
pubmed-article:18418220pubmed:meshHeadingpubmed-meshheading:18418220...lld:pubmed
pubmed-article:18418220pubmed:meshHeadingpubmed-meshheading:18418220...lld:pubmed
pubmed-article:18418220pubmed:meshHeadingpubmed-meshheading:18418220...lld:pubmed
pubmed-article:18418220pubmed:meshHeadingpubmed-meshheading:18418220...lld:pubmed
pubmed-article:18418220pubmed:meshHeadingpubmed-meshheading:18418220...lld:pubmed
pubmed-article:18418220pubmed:meshHeadingpubmed-meshheading:18418220...lld:pubmed
pubmed-article:18418220pubmed:meshHeadingpubmed-meshheading:18418220...lld:pubmed
pubmed-article:18418220pubmed:meshHeadingpubmed-meshheading:18418220...lld:pubmed
pubmed-article:18418220pubmed:meshHeadingpubmed-meshheading:18418220...lld:pubmed
pubmed-article:18418220pubmed:meshHeadingpubmed-meshheading:18418220...lld:pubmed
pubmed-article:18418220pubmed:meshHeadingpubmed-meshheading:18418220...lld:pubmed
pubmed-article:18418220pubmed:meshHeadingpubmed-meshheading:18418220...lld:pubmed
pubmed-article:18418220pubmed:meshHeadingpubmed-meshheading:18418220...lld:pubmed
pubmed-article:18418220pubmed:meshHeadingpubmed-meshheading:18418220...lld:pubmed
pubmed-article:18418220pubmed:meshHeadingpubmed-meshheading:18418220...lld:pubmed
pubmed-article:18418220pubmed:year2008lld:pubmed
pubmed-article:18418220pubmed:articleTitlePhase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS.1.2.001.lld:pubmed
pubmed-article:18418220pubmed:affiliationDepartment of Internal Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria. michael.hejna@meduniwien.ac.atlld:pubmed
pubmed-article:18418220pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18418220pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed